Osilodrostat improves quality of life for adults with Cushing’s disease

CHICAGO — Osilodrostat conferred a broad range of quality of life improvements for people with Cushing’s disease in two trials, researchers reported. As Healio previously reported in the LINC 4 trial, osilodrostat (Isturisa, Recordati) normalized urinary free cortisol excretion for 77% of adults with Cushing’s disease receiving the medication. Additionally, in the LINC 3 extension trial, 81.1% of